Compare Hormel Foods Corp (HRL) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hormel Foods Corp vs GeneDx Holdings Corp — how do they compare? Hormel Foods Corp trades at $19.19 (market cap $10.69B), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: Hormel Foods Corp is far larger — about 5.3× GeneDx Holdings Corp's market cap, and Hormel Foods Corp pays a 6.02% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hormel Foods Corp for 99 Days and GeneDx Holdings Corp for 19 Days on average.
| HRL | WGS | |
|---|---|---|
Market Cap | $10.69B | $2.02B |
Volume | 10,041,387 | 734,640 |
Sector | Consumer Staples | Health |
52-Week High | $26.50 | $167.51 |
52-Week Low | $19.42 | $34.51 |
Typical Hold Time | 99 Days | 19 Days |
Enterprise Value | $12.67B | $2.05B |
Dividend Yield | 6.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hormel Foods (HRL) trades at $19.19, down 1.84% with bearish technical signals despite recent earnings beats. The stock shows mixed fundamentals with a P/E of 31.32 above industry norms but attractive P/S of 0.88, while profitability metrics remain modest with 2.82% net margin. Recent $1.06B Brakebush acquisition aims to expand foodservice chicken presence, though dividend sustainability concerns emerge as payout ratios rise amid shrinking profit margins.
Outlook remains cautious with analyst consensus at $24.25 offering 26% upside potential, though only 20% recommend Buy. Key risks include margin compression, acquisition integration challenges, and declining organic growth. The 60-year dividend streak provides support, but investors should monitor whether earnings can sustainably cover growing payouts amid inflationary pressures.
GeneDx (WGS) trades at $67.33, down 1.75% today, with a mixed technical picture showing bearish moving averages but oversold RSI readings. The company reported Q2 2026 revenue of $114.4M, beating expectations with a return to adjusted profitability, though full-year 2026 shows negative net margins. Recent news highlights product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus is strongly bullish with an $81 price target, fundamental risks remain due to negative profitability and high valuation multiples. The stock offers potential upside if operational improvements continue, but investors face execution risk amid ongoing losses and competitive pressures in the genomics space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hormel Foods Corp
Hormel Foods is a protein-focused branded food company. Its brands include its namesake Hormel, Spam, Jennie-O, Dinty Moore, Applegate, Wholly Guacamole, and Skippy. The vast majority of the company's revenue is U.S.-based: 64% U.S. retail, 28% U.S. food service, and 8% international. By product type, in fiscal 2021, 23% of revenue was shelf-stable foods, 18% was poultry (branded and commodity), 55% was other perishable food, and 3% was other, primarily nutritional products. The company holds the number-one market position in shelf-stable meat, shelf-stable ready meals, pepperoni, natural/organic deli meat, and guacamole and the number-two position in turkey, bacon, chilled ready meals, and peanut butter.
Read more on HRL →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
